Nucleic Acid, Nucleoside, or Nucleotide – Page 2

Lilly taps Creyon’s AI-enabled oligo tech in heavily backloaded $1B deal

1 month ago talkbio0Tagged Creyon, Eli, Eli Lilly, Oligonucleotides

Creyon, Eli Lilly, Eli, Oligonucleotides

As J&J aims to ‘fundamentally change’ how bladder cancer type is treated, ImmunityBio plays defense

1 month ago talkbio0Tagged Anktiva, BCG-Unresponsive, bladder-sparing treatment, Carcinoma in Situ, gemcitabine releasing system, ImmunityBio, in situ, Malignant neoplasm of urinary bladder, Non-Muscle Invasive Bladder Neoplasms, TAR 200

TAR-200, bladder cancer, gemcitabine releasing system, non-muscle invasive bladder cancer (NMIBC), Johnson & Johnson, ImmunityBio, Anktiva, BCG-unresponsive, carcinoma in situ (CIS), bladder-sparing treatment

J&J reports durability data for bladder cancer ‘pretzel’ drug after FDA filing

1 month ago talkbio0Tagged Malignant neoplasm of urinary bladder, TAR 200, United States Food and Drug Administration, Urinary Bladder

Urinary Bladder, TAR 200, United States Food and Drug Administration, Malignant neoplasm of urinary bladder

Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects

2 months ago talkbio0Tagged 32%, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, CAR-T, Cell Therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, Neoplasms, Reindeer, Staff, United States Food and Drug Administration

Reindeer, CAR-T, Staff, Neoplasms, Cell Therapy, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, United States Food and Drug Administration, 32%

Ono Pharmaceutical and Jorna Therapeutics Partner for AI-Driven RNA Editing Therapies

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Dosage Forms, Drug Discovery, Jorna, RNA

Ono Pharmaceutical, Jorna Therapeutics, AI Drug Discovery, RNA Editing Therapies

Verve’s 2nd swing at PCSK9 editing yields clean safety profile, teeing up Lilly opt-in decision

2 months ago talkbio0Tagged Safety, VERVE-102

VERVE-102, Safety

Tome Bio founders wrangle jumping genes to create new programmable gene insertion tool

2 months ago talkbio0Tagged Clustered Regularly Interspaced Short Palindromic Repeats, PGI, Retrotransposons, Technology

PGI, Technology, Retrotransposons, Clustered Regularly Interspaced Short Palindromic Repeats

Atsena reels in $150M to advance work on ocular gene therapies

2 months ago talkbio0Tagged Atsena, ATSN-101, ATSN-201, Blindness, Cloning Vectors, Dependovirus, Hereditary, Retinal Diseases, Retinoschisis, Juvenile, X-Linked, United States Food and Drug Administration

Atsena, Retinoschisis, Juvenile, X-Linked, United States Food and Drug Administration, Dependovirus, Cloning Vectors, Hereditary, Retinal Diseases, Blindness, ATSN-201, ATSN-101